A Novel ANG-BSA/BCNU/ICG MNPs Integrated for Targeting Therapy of Glioblastoma.

IF 2.7 4区医学 Q3 ONCOLOGY

Technology in Cancer Research & Treatment Pub Date : 2024-01-01 DOI:10.1177/15330338241281321

Li-Hong Liu, Yu-Feng Liu, Hong-Bo Zhang, Xiao-Lei Liu, Han-Wen Zhang, Biao Huang, Fan Lin, Wei-Hua Li

{"title":"A Novel ANG-BSA/BCNU/ICG MNPs Integrated for Targeting Therapy of Glioblastoma.","authors":"Li-Hong Liu, Yu-Feng Liu, Hong-Bo Zhang, Xiao-Lei Liu, Han-Wen Zhang, Biao Huang, Fan Lin, Wei-Hua Li","doi":"10.1177/15330338241281321","DOIUrl":null,"url":null,"abstract":"Purpose: Develop an albumin nanoparticle-based nanoprobe for targeted glioblastoma (GBM) diagnosis and treatment, utilizing Angopep-2 for low-density lipoprotein receptor-related protein (LRP) targeting.Methods: Combined albumin-coated superparamagnetic iron oxide (SPIO), Carmustine (BCNU), and indocyanine green (ICG). Assessed morphology, size, Zeta potential, fluorescence, and drug encapsulation. Conducted in vitro fluorescence/MRI imaging and cell viability assays, and in vivo nanoprobe accumulation evaluation in brain tumors.Results: ANG-BSA/BCNU/ICG MNPs exhibited superior targeting and cytotoxicity against GBM cells in vitro. In vivo, enhanced brain tumor accumulation during imaging was observed.Conclusion: This targeted imaging and drug delivery system holds promise for efficient GBM therapy and intraoperative localization, addressing Blood-brain barrier (BBB) limitations with precise drug delivery and imaging capabilities.","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"23 ","pages":"15330338241281321"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526396/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Technology in Cancer Research & Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15330338241281321","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Develop an albumin nanoparticle-based nanoprobe for targeted glioblastoma (GBM) diagnosis and treatment, utilizing Angopep-2 for low-density lipoprotein receptor-related protein (LRP) targeting.

Methods: Combined albumin-coated superparamagnetic iron oxide (SPIO), Carmustine (BCNU), and indocyanine green (ICG). Assessed morphology, size, Zeta potential, fluorescence, and drug encapsulation. Conducted in vitro fluorescence/MRI imaging and cell viability assays, and in vivo nanoprobe accumulation evaluation in brain tumors.

Results: ANG-BSA/BCNU/ICG MNPs exhibited superior targeting and cytotoxicity against GBM cells in vitro. In vivo, enhanced brain tumor accumulation during imaging was observed.

Conclusion: This targeted imaging and drug delivery system holds promise for efficient GBM therapy and intraoperative localization, addressing Blood-brain barrier (BBB) limitations with precise drug delivery and imaging capabilities.

查看原文本刊更多论文

用于胶质母细胞瘤靶向治疗的新型 ANG-BSA/BCNU/ICG MNPs。

目的：开发一种基于白蛋白纳米粒子的纳米探针，用于胶质母细胞瘤（GBM）的靶向诊断和治疗，利用 Angopep-2 实现低密度脂蛋白受体相关蛋白（LRP）的靶向：将白蛋白包被的超顺磁性氧化铁（SPIO）、卡莫司汀（BCNU）和吲哚青绿（ICG）结合起来。评估形态、大小、Zeta 电位、荧光和药物包囊。进行体外荧光/MRI 成像和细胞活力测定，以及体内纳米探针在脑肿瘤中的积累评估：结果：ANG-BSA/BCNU/ICG MNPs在体外对GBM细胞表现出卓越的靶向性和细胞毒性。结果：ANG-BSA/BCNU/ICG MNPs 在体外对 GBM 细胞表现出卓越的靶向性和细胞毒性，在体内成像过程中观察到脑肿瘤蓄积增强：这种靶向成像和给药系统有望实现高效的 GBM 治疗和术中定位，通过精确给药和成像功能解决血脑屏障（BBB）的限制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Technology in Cancer Research & Treatment 医学-肿瘤学

CiteScore

4.40

自引率

0.00%

发文量

202

审稿时长

2 months

期刊介绍： Technology in Cancer Research & Treatment (TCRT) is a JCR-ranked, broad-spectrum, open access, peer-reviewed publication whose aim is to provide researchers and clinicians with a platform to share and discuss developments in the prevention, diagnosis, treatment, and monitoring of cancer.